Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTB003 in healthy volunteers
NCT07182552Phase 1Enrolling by invitation
- Sponsor
- Nanjing Chia-Tai Tianqing Pharmaceutical
- Start
- Jun 2025
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in thyroid eye disease (TED) comparing NTB003 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events. Started Jun 2025; status: enrolling by invitation.
02
Drugs
NTB003
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT07182552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07182552.